BridgeBio Pharma (BBIO) EBT (2018 - 2026)
BridgeBio Pharma (BBIO) posted EBT of -$120.0 million for Q1 2026, up 38.37% sequentially from -$194.8 million in Q4 2025, and up 1.83% YoY from -$117.9 million in Q1 2025.
BridgeBio Pharma (BBIO) EBT (2018 - 2026) Analysis & Trends
BridgeBio Pharma has reported EBT for 9 years, with the latest figure at -$120.0 million in Q1 2026.
- Quarterly EBT rose 1.83% year-over-year to -$120.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$682.9 million (down 8.69% YoY) and the FY2025 annual result came in at -$732.5 million, down 35.1% from the prior year.
- EBT climbed to -$120.0 million in Q1 2026 per BBIO's latest filing, from -$194.8 million in the prior quarter.
- Over five years, EBT peaked at -$35.0 million in Q1 2024 and troughed at -$266.2 million in Q4 2024.
- A 5-year average of -$154.3 million and a median of -$164.3 million in 2024 frame the typical range for EBT.
- The sharpest annual moves came in 2024 and 2025: EBT surged 76.34% in 2024, then slumped 249.3% in 2025.
- Over 5 years, EBT stood at -$145.1 million in 2022, then slumped by 39.39% to -$202.3 million in 2023, then sank by 31.6% to -$266.2 million in 2024, then advanced by 26.85% to -$194.8 million in 2025, then jumped by 38.37% to -$120.0 million in 2026.
- According to Business Quant data, EBT over the past three periods registered -$120.0 million, -$194.8 million, and -$186.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.39 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 541.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 312.46 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2,828.29 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 177.81 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -11.37 Mn |
| 10 | BridgeBio Pharma | 15.60 Bn | 14.89 Bn | 228.63 Mn | -155.89 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -155.89 Mn |
| Mar 31, 2026 | -120.03 Mn |
| Dec 31, 2025 | -194.76 Mn |
| Sep 30, 2025 | -186.48 Mn |
| Jun 30, 2025 | -181.66 Mn |
| Mar 31, 2025 | -122.26 Mn |
| Dec 31, 2024 | -266.24 Mn |
| Sep 30, 2024 | -164.25 Mn |
| Jun 30, 2024 | -75.54 Mn |
| Mar 31, 2024 | -35.00 Mn |
| Dec 31, 2023 | -202.30 Mn |
| Sep 30, 2023 | -174.21 Mn |
| Jun 30, 2023 | -166.62 Mn |
| Mar 31, 2023 | -147.91 Mn |
| Dec 31, 2022 | -145.13 Mn |
| Sep 30, 2022 | -146.52 Mn |
| Jun 30, 2022 | -100.50 Mn |
| Mar 31, 2022 | -194.27 Mn |
| Dec 31, 2021 | -180.57 Mn |
| Sep 30, 2021 | -174.56 Mn |